NasdaqCM:SLSBiotechs
SELLAS Life Sciences Group (SLS) Is Up 13.7% After Daiwa Boosts Stake Ahead Of REGAL Readout – Has The Bull Case Changed?
Daiwa Securities recently sharply increased its stake in SELLAS Life Sciences Group, as the company reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis.
This convergence of an imminent pivotal trial readout and growing institutional ownership highlights how clinical progress and balance-sheet strength are intersecting for SELLAS.
Next, we’ll explore how the approaching REGAL Phase 3 readout shapes SELLAS Life Sciences...